Brian Krzanich, chief executive officer of Intel Corp., right, shows the collision avoidance feature of an AscTec Firefly drone with Intel RealSense cameras during the 2015 Consumer Electronics Show (CES) in Las Vegas, Nevada.Intel is spinning out its artificial intelligence robotics and biometric venture as more companies bet big on automation tools.The new company, known as RealSense, was announced Friday and comes alongside a $50-million Series A funding round that includes MediaTek Innovation Fund and I ...

METTAWA, Ill., July 11, 2025 (GLOBE NEWSWIRE) -- Brunswick Corporation, (NYSE:BC), the world’s leading marine technology company, has been recognized on TIME's list of America's Best Midsize Companies for 2025. Of the 500 companies recognized, Brunswick ranked 16th within the Engineering and Manufacturing category and 94th overall. This award reflects Brunswick’s exceptional performance in three focus areas: employee satisfaction, revenue growth, and sustainability transparency. “We are honored to once agai ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients ...

Net income attributable to owners increased to $57.3 million, or $2.49 per diluted share compared to $27.3 million, or $1.13 per diluted share in Q2-24.Cash flows provided by operating activities were $40.2 million compared to $40.6 million in Q2-24, a decrease of $0.4 million mainly attributable to lower segment EBITDA.Franchise segment normalized adjusted EBITDA(1) increased by 3% to attain $54.0 million in the quarter, compared to $52.6 million in Q2-24.Normalized adjusted EBITDA(1) decreased 5% to reach ...

RETRANSMISSION: HIVE Digital Technologies Exceeds 12 EH/s Milestone, Achieves $250 Million Annual Run Rate Revenue as Paraguay Expansion ProgressesJuly 11, 2025 6:00 AM EDT | Source: HIVE Digital Technologies Ltd.This news release constitutes a "designated news release for the purposes of the Company's amended and restated prospectus supplement dated May 14, 2025, to its short form base shelf prospectus dated September 11, 2024.San Antonio, Texas--(Newsfile Corp. - July 11, 2025) - HIVE Digita ...

SHENZHEN, China, July 11, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today announced that it is evaluating the integration of Solana as a cornerstone of its forward-looking cryptocurrency treasury strategy, which was approved by the Board of Directors in June 2025. Mr. Weidong Luo, Chairman and Chief Executive Officer of Aurora Mobile, commented, "Our potential Solana-fo ...

SHENZHEN, China, July 11, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today announced that it is evaluating the integration of Solana as a cornerstone of its forward-looking cryptocurrency treasury strategy, which was approved by the Board of Directors in June 2025. Mr. Weidong Luo, Chairman and Chief Executive Officer of Aurora Mobile, commented, "Our potential Solana-fo ...

市场潜力与用户数据 - 预计到2030年，美国市场的潜在患者将超过170百万，当前市场渗透率为5%[14] - 在ACHIEVE-1试验中，约75%的患者达到了ADA HbA1c目标<7%，约67%的患者达到了HbA1c≤6.5%[27] - 在ACHIEVE-1试验中，约66%的患者实现了≥5%的体重减少，约33%的患者实现了≥10%的体重减少[30] 产品研发与临床试验 - Orforglipron在ACHIEVE-1试验中，所有剂量均显示出相对于安慰剂的显著优势，HbA1c的变化分别为-1.3%、-1.5%、-1.6%和-0.1%[27] - Orforglipron的体重变化结果显示，12 mg和36 mg剂量的患者分别实现了-6.1%和-7.9%的体重减少[30] - 预计Orforglipron的肥胖适应症提交时间为2025年第四季度，2型糖尿病的提交时间为2026年上半年[23] - 预计到2026年下半年，Retatrutide在肥胖、骨关节炎和阻塞性睡眠呼吸暂停的适应症提交[41] - 预计TRIUMPH-1试验的顶线结果将在2025年第三季度公布[39] - 预计TRIUMPH-4试验的顶线结果将在2025年第四季度公布[48] - 预计2025年下半年完成Eloralintide的第二阶段单药研究[63] - 公司计划在2025年发布多个第三阶段数据，包括tirzepatide、orforglipron和retatrutide[70] - 公司预计到2027年底推出两种新的肠促胰素疗法[70] 安全性与耐受性 - Orforglipron的安全性和耐受性与注射型GLP-1药物一致，3 mg、12 mg和36 mg剂量的因不良事件而停药的比例分别为6%、4%和8%[32] - Dulaglutide相较于安慰剂降低了12%的MACE-3风险，MACE-3包括心血管死亡、心肌梗死或中风[51] - REWIND研究显示Dulaglutide在主要和次要预防人群中均表现出心血管益处[55] - Eloralintide的GI副作用发生率低于10%[60] 新产品与市场扩张 - Tirzepatide的最大耐受剂量（MTD）为每周15毫克[51] - Eloralintide在12周内实现了最高11.3%的体重减轻[60] - 在Eloralintide的不同剂量中，19.2%的参与者报告了食欲减退[62] - 全球超过10亿人可能受益于这些创新药物[71]

你用手机壳吗？不少人可能都体会过，刚购买的手机壳散发出浓烈的塑料味，而当手机发热 时，刺鼻的味道更明显。而这很有可能是有毒有害物质超标的信号！ 廉价手机壳 暗含3大隐患 "刚拆封的手机壳就有刺鼻气味，用久了连手机都沾上怪味，手机用了发热，刺鼻味就会更明 显。"一位消费者告诉封面新闻记者，自己很喜欢从电商平台上买手机壳，购入价格基本在30 以内，便宜的还会到个位数。" 但有些便宜的手机壳打开就知道（有味道），我通常都放几天 才用 。" 消费者对劣质手机壳的吐槽并非个例。记者在某电商平台销量靠前的"9.9元包邮"手机 壳，"拆封后即散发浓烈塑料味"的评论居高不下，还有消费者指出，使用一个月后，手机壳 还有残留的异味难以消散。 手机壳为何成为"健康隐形杀手"？记者调查发现 该行业准入门槛极低，仅需购买模具即可批 量生产 。许多小作坊为压缩成本， 使用回收塑料、工业级染料，甚至违规添加廉价助剂 。 某从业者透露："正规原料每吨上万元，掺入废塑料成本能降三分之二。" 回收"垃圾"塑料 部分商家可能会回收 医疗废料、电子垃圾 ，简单处理后注塑成型，这样的手机壳往往携带 塑化剂、多环芳烃、重金属 等有毒物质。 多环芳烃 中 ...

June 12, 2025 Cautionary Note and Disclaimer Presentation of Initial SGR-1505 Phase 1 Clinical Data This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schrödinger, Inc. ("we," "us," "our," "Schrödinger," or the "Company") contained in this presentation, including, without limitation, statements regardi ...